Data / Drug companies / Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC: 38 products in the FDA NDC directory, labeler code 0024
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Sanofi-Aventis U.S. LLC (labeler code 0024) lists 38 products in the FDA National Drug Code Directory, covering 20 finished drugs by generic name. By type: 38 prescription drugs. Its main marketing category is biologics (BLA). The newest product started marketing on July 9, 2026.
The request: Watch Sanofi-Aventis U.S. LLC (FDA labeler code 0024): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 0024
- Products in commercial distribution
- 38
- Packages
- 55
- Finished drugs by generic name
- 20
- Prescription products
- 38
- Over the counter products
- 0
- Flagged as original packager
- 38 of 38 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- November 17, 1997
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Biologics (BLA) | 25 | 65.8% |
| New drug applications (NDA) | 13 | 34.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 38 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Sarilumab | 4 | 1 |
| Dupilumab | 4 | 1 |
| Insulin lispro | 3 | 4 |
| Irbesartan and hydrochlorothiazide | 2 | 15 |
| Insulin glargine | 2 | 5 |
| Sodium ferric gluconate complex | 2 | 1 |
| Rasburicase | 2 | 1 |
| Isatuximab | 2 | 1 |
| Insulin aspart-szjj | 2 | 1 |
| Irbesartan | 2 | 27 |
| Ziv-aflibercept | 2 | 1 |
| Clopidogrel | 2 | 13 |
| Alirocumab | 2 | 2 |
| Fexinidazole | 1 | 1 |
| Dronedarone | 1 | 2 |
| Plerixafor | 1 | 13 |
| Isatuximab-irfc | 1 | 1 |
| Insulin glargine and lixisenatide | 1 | 1 |
| Cabazitaxel | 1 | 1 |
| Primaquine phosphate | 1 | 5 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 20 | 52.6% |
| Tablet, film coated | 8 | 21.1% |
| Kit | 3 | 7.9% |
| Injection | 2 | 5.3% |
| Injection, solution, concentrate | 2 | 5.3% |
| Solution, concentrate | 2 | 5.3% |
| Tablet | 1 | 2.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Insulin Analog | 8 |
| Angiotensin 2 Receptor Blocker | 4 |
| Interleukin-6 Receptor Antagonist | 4 |
| Interleukin-4 Receptor alpha Antagonist | 4 |
| CD38-directed Cytolytic Antibody | 3 |
| Thiazide Diuretic | 2 |
| Parenteral Iron Replacement | 2 |
| Phosphate Binder | 2 |
| Vascular Endothelial Growth Factor Inhibitor | 2 |
| P2Y12 Platelet Inhibitor | 2 |
| PCSK9 Inhibitor | 2 |
| Nitroimidazole Antimicrobial | 1 |
| Antiarrhythmic | 1 |
| Hematopoietic Stem Cell Mobilizer | 1 |
| GLP-1 Receptor Agonist | 1 |
| Antimalarial | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sarclisa Escena | 0024-0674 | Injection, solution | Biologics (BLA) | July 9, 2026 |
| Merilog | 0024-5928 | Injection, solution | Biologics (BLA) | February 14, 2025 |
| Merilog | 0024-5927 | Injection, solution | Biologics (BLA) | February 14, 2025 |
| Fexinidazole | 0024-4512 | Tablet | New drug applications (NDA) | July 16, 2021 |
| Dupixent | 0024-5919 | Injection, solution | Biologics (BLA) | June 14, 2021 |
| Dupixent | 0024-5915 | Injection, solution | Biologics (BLA) | June 19, 2020 |
| Sarclisa | 0024-0656 | Injection, solution, concentrate | Biologics (BLA) | March 2, 2020 |
| Sarclisa | 0024-0654 | Injection, solution, concentrate | Biologics (BLA) | March 2, 2020 |
| Admelog | 0024-5926 | Injection, solution | Biologics (BLA) | October 19, 2018 |
| Dupixent | 0024-5918 | Injection, solution | Biologics (BLA) | October 19, 2018 |
| Admelog | 0024-5925 | Injection, solution | Biologics (BLA) | December 11, 2017 |
| Admelog | 0024-5924 | Injection, solution | Biologics (BLA) | December 11, 2017 |
| Kevzara | 0024-5922 | Injection, solution | Biologics (BLA) | May 22, 2017 |
| Kevzara | 0024-5920 | Injection, solution | Biologics (BLA) | May 22, 2017 |
| Kevzara | 0024-5910 | Injection, solution | Biologics (BLA) | May 22, 2017 |
| Kevzara | 0024-5908 | Injection, solution | Biologics (BLA) | May 22, 2017 |
| Dupixent | 0024-5914 | Injection, solution | Biologics (BLA) | March 28, 2017 |
| Soliqua 100/33 | 0024-5761 | Injection, solution | Biologics (BLA) | November 21, 2016 |
| Praluent | 0024-5902 | Injection, solution | Biologics (BLA) | July 24, 2015 |
| Praluent | 0024-5901 | Injection, solution | Biologics (BLA) | July 24, 2015 |
| TOUJEO Max | 0024-5871 | Injection, solution | Biologics (BLA) | February 15, 2015 |
| Toujeo | 0024-5869 | Injection, solution | Biologics (BLA) | February 15, 2015 |
| Ferrlecit | 0024-2794 | Injection | New drug applications (NDA) | July 7, 2014 |
| Mozobil | 0024-5862 | Injection, solution | New drug applications (NDA) | September 1, 2013 |
| Avalide | 0024-5856 | Tablet, film coated | New drug applications (NDA) | January 1, 2013 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.